Sign In
Buy REGN
$618.03
+5.53 (+0.90%)
At Close: Jun 23, 2026
Regeneron's Applications for gMG Drug Accepted by FDA and EMA
03:26pm, Tuesday, 23'rd Jun 2026
Regeneron's cemdisiran won FDA Priority Review and EMA filing acceptance for gMG, backed by phase III data and a potentially unique dosing schedule.
2 Underrated Weight Loss Stocks to Buy and Hold
02:45am, Tuesday, 23'rd Jun 2026
They look well-positioned to grab a slice of the fast-growing anti-obesity market.
Breakfast News: AbbVie's $11 Billion Pounce
07:30am, Monday, 22'nd Jun 2026
AbbVie reportedly set to take over Apogee, Satya Nadella wants to upturn AI, and more
Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
07:00am, Monday, 22'nd Jun 2026
Cemdisiran could be the first siRNA approved for the treatment of gMG and only therapy to be offered subcutaneously with four times a year dosing
This Stock Is Up 58% This Year. Is It too Late to Buy?
02:30am, Wednesday, 17'th Jun 2026
There could be additional catalysts for this drugmaker over the next year.
Here's Why Regeneron (REGN) is a Strong Value Stock
10:41am, Friday, 12'th Jun 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
10:00am, Thursday, 11'th Jun 2026
NEW YORK, June 11, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors
REGN Investors Have Opportunity to Join Regeneron Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
04:00pm, Wednesday, 10'th Jun 2026
[url="]The Schall Law Firm[/url], a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron P
REGN Investors Have Opportunity to Join Regeneron Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
03:00pm, Wednesday, 10'th Jun 2026
LOS ANGELES--(BUSINESS WIRE)---- $REGN--REGN Investors Have Opportunity to Join Regeneron Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
01:35pm, Tuesday, 09'th Jun 2026
NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN). Suc
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
05:38pm, Monday, 08'th Jun 2026
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Regeneron: 'Buy' Revenue Growth And Two Extensive Drug Development Opportunities
02:48am, Monday, 08'th Jun 2026
Regeneron Pharmaceuticals remains a "Buy," driven by EYLEA HD expansion, strong DUPIXENT growth, and promising pipeline assets. EYLEA HD U.S. sales surged 52% in Q1 2026, offsetting competitive pressu
REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics
02:25pm, Thursday, 04'th Jun 2026
Regeneron expands its CytomX partnership to develop conditionally activated bispecific cancer therapies, with potential milestones nearing $4 billion.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
10:00am, Thursday, 04'th Jun 2026
NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors ar
Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
07:00am, Thursday, 04'th Jun 2026
TARRYTOWN, N.Y., June 04, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new clinical data and research from its metabolic disease, ophthalmology and rare
